

November 26, 2018



## Emmaus Life Sciences to Participate in the Piper Jaffray Healthcare Conference

TORRANCE, Calif.--(BUSINESS WIRE)-- [Emmaus Life Sciences, Inc.](http://www.emmausmedical.com) (Emmaus), a leader in sickle cell disease treatment, announced today that its CEO, Yutaka Niihara, MD, MPH will present at the 30<sup>th</sup> Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018, at 8:50 a.m. ET in New York, New York. A webcast of the event will be available at <https://bit.ly/2P49yYl>.

### About Emmaus Life Sciences, Inc.

Emmaus Life Sciences, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. Its lead product, Endari<sup>TM</sup> (L-glutamine oral powder), demonstrated positive clinical results in the completed Phase 3 clinical trial for sickle cell anemia and sickle  $\beta$ 0-thalassemia and has received U.S. FDA approval. Visit: <http://www.emmausmedical.com>.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20181126005776/en/>

LaVoie Health Science

Katie Gallagher, 617-374-8800 x109

[kgallagher@lavoiehealthscience.com](mailto:kgallagher@lavoiehealthscience.com)

Source: Emmaus Life Sciences, Inc.